Key result
Concomitant use of SSRIs and NSAIDs increased the risk of any psychiatric contact (HR 1.22; 95% CI 1.07-1.38), whereas low-dose acetylsalicylic acid reduced this risk (HR 0.74; 95% CI 0.56-0.98).
Why the study?
Does concomitant use of NSAIDs or paracetamol with SSRIs affect psychiatric outcomes and mortality in incident SSRI users?
Cohort (n=123,351)
Does concomitant use of NSAIDs or paracetamol with SSRIs affect psychiatric outcomes and mortality in incident SSRI users?
Hazard Ratio: 1.22 (95% CI 1.07–1.38)
While low-dose aspirin and ibuprofen may reduce psychiatric contacts in SSRI users, concomitant use of paracetamol, diclofenac, and COX-2 inhibitors is associated with increased mortality.
No takes yet. Share an insight, caveat, or question.
May warrant caution with SSRI-NSAID or paracetamol co-use due to variable risks; leaves open net psychiatric benefit by agent.
Köhler‐Forsberg et al. (2015) conducted a cohort in Depression (n=123,351). Concomitant use of SSRIs and NSAIDs or paracetamol vs. Periods of SSRI use only was evaluated on Any psychiatric contact (HR 1.22, 95% CI 1.07-1.38). Concomitant use of SSRIs and NSAIDs increased the risk of any psychiatric contact (HR 1.22; 95% CI 1.07-1.38), whereas low-dose acetylsalicylic acid reduced this risk (HR 0.74; 95% CI 0.56-0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: